NASDAQ:BIIB

Biogen (BIIB) Stock Forecast, Price & News

$257.68

-1.25 (-0.48%)

(As of 09/22/2023 ET)

Compare

Today's Range: $257.14
▼
$260.72
50-Day Range: $253.30
▼
$278.40
52-Week Range: $194.45
▼
$319.76

Volume: 800,820 shs
Average Volume: 723,311 shs
Market Capitalization: $37.32 billion

P/E Ratio: 14.03
Dividend Yield: N/A
Price Target: $325.36

Biogen MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.81 Rating Score
Upside/Downside: 26.3% Upside
$325.36 Price Target
Short Interest: Healthy
2.18% of Float Sold Short
Dividend Strength: N/A
Sustainability: -2.45
Upright™ Environmental Score
News Sentiment: 1.11
Based on 6 Articles This Week
Insider Trading: Selling Shares
$139,037 Sold Last Quarter
Proj. Earnings Growth: 6.89%
From $15.25 to $16.30 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.83 out of 5 stars

Medical Sector

61st out of 968 stocks

Biological Products, Except Diagnostic Industry

6th out of 157 stocks

4.4

Analyst's Opinion

Consensus Rating
Biogen has received a consensus rating of Moderate Buy. The company's average rating score is 2.81, and is based on 22 buy ratings, 5 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $325.36, Biogen has a forecasted upside of 26.3% from its current price of $257.68.
Amount of Analyst Coverage
Biogen has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

3.0

Short Interest

Percentage of Shares Shorted
2.18% of the float of Biogen has been sold short.
Short Interest Ratio / Days to Cover
Biogen has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Biogen has recently increased by 3.63%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Biogen does not currently pay a dividend.
Dividend Growth
Biogen does not have a long track record of dividend growth.

3.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Biogen has received a 28.69% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Multiple sclerosis medication", "Biopharmaceuticals", and "Interferons" products. See details.
Environmental Sustainability
The Environmental Impact score for Biogen is -2.45.

2.8

News and Social Media Coverage

News Sentiment
Biogen has a news sentiment score of 1.11. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Biogen this week, compared to 15 articles on an average week.
Search Interest
Only 16 people have searched for BIIB on MarketBeat in the last 30 days. This is a decrease of -62% compared to the previous 30 days.
MarketBeat Follows
11 people have added Biogen to their MarketBeat watchlist in the last 30 days. This is an increase of 38% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Biogen insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $139,037.00 in company stock.
Percentage Held by Insiders
Only 0.60% of the stock of Biogen is held by insiders.
Percentage Held by Institutions
85.99% of the stock of Biogen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Biogen are expected to grow by 6.89% in the coming year, from $15.25 to $16.30 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Biogen is 14.03, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.70.
Price to Earnings Ratio vs. Sector
The P/E ratio of Biogen is 14.03, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 143.85.
Price to Earnings Growth Ratio
Biogen has a PEG Ratio of 2.82. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Biogen has a P/B Ratio of 2.77. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Biogen (NASDAQ:BIIB) Stock

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

BIIB Price History

30 days | 90 days | 365 days | Advanced Chart

BIIB Stock News Headlines

September 21, 2023 | nasdaq.com

Reata Pharma Stockholders Approve Acquisition By Biogen

September 21, 2023 | businesswire.com

Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.

September 23, 2023 | Legacy Research (Ad)

Reverse ‘money machines’ popping up across America

If you’ve been to a concert venue, stadium, or airport, you’ve almost certainly walked by one without knowing. The experts are calling it a 'Reverse ATM' Why are these machines suddenly appearing out of nowhere? And what does it mean for your money?

September 20, 2023 | finance.yahoo.com

GE Healthcare: why it's still waiting on its Leqembi windfall

September 13, 2023 | finance.yahoo.com

Biogen Inc.'s (NASDAQ:BIIB) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

September 12, 2023 | msn.com

Intas reportedly readying bid of up to $1B for Biogen biosimilars unit

September 12, 2023 | finance.yahoo.com

Biogen Inc. (BIIB) Stock Moves -0.19%: What You Should Know

September 12, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Biogen (BIIB)

September 23, 2023 | Legacy Research (Ad)

Reverse ‘money machines’ popping up across America

September 11, 2023 | stocknews.com

3 Biotech Gainers to Consider

September 11, 2023 | seekingalpha.com

Biogen Inc. (BIIB) Morgan Stanley 21st Annual Global Healthcare Conference (Transcript)

September 9, 2023 | morningstar.com

Biogen Inc BIIB Stock Quote

September 8, 2023 | finance.yahoo.com

Is Eli Lilly Stock A Buy Now That It Has Hit A Profit-Taking Zone?

September 7, 2023 | finance.yahoo.com

The Petri Dish: Biogen secures $1.5B loan; Mersana CEO departs after trial failure

September 7, 2023 | msn.com

HSBC Initiates Coverage of Biogen (BIIB) with Buy Recommendation

September 6, 2023 | msn.com

Biogen names Dr. Jane Grogan head of research effective Oct. 2

September 6, 2023 | finance.yahoo.com

Biogen Appoints Jane Grogan as Head of Research

September 6, 2023 | finance.yahoo.com

Octave Bioscience Releases Multiple Sclerosis Study in Biogen Partnership

September 5, 2023 | finance.yahoo.com

Biogen's (BIIB) Stock Outperforms Industry YTD: Here's Why

September 5, 2023 | seekingalpha.com

Biogen: Leqembi Could Boost Prospects Until Acquisition Comes Into Play

September 2, 2023 | finance.yahoo.com

Biogen Inc. (NASDAQ:BIIB) is favoured by institutional owners who hold 89% of the company

August 31, 2023 | reuters.com

Sage Therapeutics to cut 40% of jobs after depression drug setback

August 31, 2023 | msn.com

Sage Therapeutics to cut about 188 jobs after depression drug setback

August 31, 2023 | msn.com

Sage cuts 40% of staff in portfolio shake-up ahead of Zurzuvae launch

August 31, 2023 | finance.yahoo.com

UPDATE 1-Sage Therapeutics to cut about 188 jobs after depression drug setback

August 29, 2023 | finance.yahoo.com

Roche's (RHHBY) Evrysdi Gets Label Expansion in EU for Newborns

August 29, 2023 | markets.businessinsider.com

RBC Capital Remains a Buy on Biogen (BIIB)

See More Headlines

Receive BIIB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat's FREE daily newsletter.

BIIB Company Calendar

Last Earnings: 7/25/2023
Today: 9/22/2023
Next Earnings (Estimated): 10/24/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:BIIB
CUSIP: 09062X10
CIK: 875045
Web: www.biogen.com
Phone: (617) 679-2000
Fax: 617-679-2617
Employees: 8,725
Year Founded: 1978

Price Target and Rating

Average Stock Price Forecast: $325.36
High Stock Price Forecast: $381.00
Low Stock Price Forecast: $269.00
Forecasted Upside/Downside: +26.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.81
Research Coverage: 27 Analysts

Profitability

EPS (Most Recent Fiscal Year): $18.37
Trailing P/E Ratio: 14.03
Forward P/E Ratio: 16.90
P/E Growth: 2.82
Net Income: $3.05 billion
Net Margins: 26.72%
Pretax Margin: 31.30%
Return on Equity: 17.33%
Return on Assets: 9.51%

Debt

Debt-to-Equity Ratio: 0.43
Current Ratio: 3.27
Quick Ratio: 2.86

Sales & Book Value

Annual Sales: $10.17 billion
Price / Sales: 3.67
Cash Flow: $21.28 per share
Price / Cash Flow: 12.11
Book Value: $92.97 per share
Price / Book: 2.77

Miscellaneous

Outstanding Shares: 144,820,000
Free Float: 143,954,000
Market Cap: $37.32 billion
Optionable: Optionable
Beta: 0.13

Social Links

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Christopher A. Viehbacher (Age 62)
Pres, CEO & Director
Comp: $487.94k

Mr. Michael R. McDonnell CPA (Age 59)
Exec. VP & CFO
Comp: $2.12M

Ms. Nicole Murphy
Head of Pharmaceutical Operations & Technology

Ms. Susan H. Alexander Esq. (Age 66)
Exec. VP, Chief Legal Officer & Sec.
Comp: $2.2M

Dr. Ginger Gregory (Age 55)
Exec. VP & Chief HR Officer
Comp: $1.59M

Ms. Robin C. Kramer (Age 57)
Sr. VP & Chief Accounting Officer

Mr. Charles E. Triano
Sr. VP & Head of Investor Relations

Ms. Natacha Gassenbach
Chief Communication Officer & Head of Corp. Affairs

Mr. Adam Keeney Ph.D.
Exec. VP & Head of Corp. Devel.

Ms. Alisha A. Alaimo
Pres & Head of North America

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BIIB Stock - Frequently Asked Questions

Should I buy or sell Biogen stock right now?: 27 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last twelve months. There are currently 5 hold ratings and 22 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BIIB shares.
View BIIB analyst ratings or view top-rated stocks.
What is Biogen's stock price forecast for 2023?: 27 analysts have issued 12-month price objectives for Biogen's stock. Their BIIB share price forecasts range from $269.00 to $381.00. On average, they predict the company's stock price to reach $325.36 in the next twelve months. This suggests a possible upside of 26.3% from the stock's current price.
View analysts price targets for BIIB or view top-rated stocks among Wall Street analysts.
How have BIIB shares performed in 2023?: Biogen's stock was trading at $276.92 at the beginning of 2023. Since then, BIIB shares have decreased by 6.9% and is now trading at $257.68.
View the best growth stocks for 2023 here.
When is Biogen's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, October 24th 2023.
View our BIIB earnings forecast.
How were Biogen's earnings last quarter?: Biogen Inc. (NASDAQ:BIIB) posted its quarterly earnings data on Tuesday, July, 25th. The biotechnology company reported $4.02 EPS for the quarter, beating the consensus estimate of $3.77 by $0.25. The biotechnology company earned $2.46 billion during the quarter, compared to analysts' expectations of $2.36 billion. Biogen had a net margin of 26.72% and a trailing twelve-month return on equity of 17.33%. Biogen's revenue was down 5.1% on a year-over-year basis. During the same period last year, the company earned $5.25 earnings per share.
Read the conference call transcript.
What ETFs hold Biogen's stock?: ETFs with the largest weight of Biogen (NASDAQ:BIIB) stock in their portfolio include Horizon Kinetics Medical ETF (MEDX), VanEck Biotech ETF (BBH), Invesco Biotechnology & Genome ETF (PBE), Subversive Mental Health ETF (SANE), iShares Neuroscience and Healthcare ETF (IBRN), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB) and Goldman Sachs Future Health Care Equity ETF (GDOC).
What guidance has Biogen issued on next quarter's earnings?: Biogen issued an update on its FY 2023 earnings guidance on Tuesday, July, 25th. The company provided earnings per share (EPS) guidance of $15.00-$16.00 for the period, compared to the consensus EPS estimate of $15.42. The company issued revenue guidance of -.
What is Michel Vounatsos' approval rating as Biogen's CEO?: 394 employees have rated Biogen Chief Executive Officer Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among the company's employees. 72.0% of employees surveyed would recommend working at Biogen to a friend.

What other stocks do shareholders of Biogen own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Netflix (NFLX), Tesla (TSLA), Alibaba Group (BABA), Amgen (AMGN), Walt Disney (DIS), Intel (INTC), Micron Technology (MU) and Boeing (BA).
What is Biogen's stock symbol?: Biogen trades on the NASDAQ under the ticker symbol "BIIB."
Who are Biogen's major shareholders?: Biogen's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (9.71%), State Street Corp (4.75%), Geode Capital Management LLC (2.20%), Bank Julius Baer & Co. Ltd Zurich (1.44%), Clearbridge Investments LLC (1.26%) and Northern Trust Corp (1.10%). Insiders that own company stock include Alfred Sandrock, Brian S Posner, Ginger Gregory, Michel Vounatsos, Priya Singhal and Susan H Alexander.
View institutional ownership trends.
How do I buy shares of Biogen?: Shares of BIIB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Biogen's stock price today?: One share of BIIB stock can currently be purchased for approximately $257.68.
How much money does Biogen make?: Biogen (NASDAQ:BIIB) has a market capitalization of $37.32 billion and generates $10.17 billion in revenue each year. The biotechnology company earns $3.05 billion in net income (profit) each year or $18.37 on an earnings per share basis.
How many employees does Biogen have?: The company employs 8,725 workers across the globe.
Does Biogen have any subsidiaries?: The following companies are subsidiares of Biogen: BIIB Colombia S.A.S., Biogen (Argentina) SRL, Biogen (Bermuda) Technologies Ltd., Biogen (Czech Republic) s.r.o., Biogen (Denmark) A/S, Biogen (RTP) Realty LLC, Biogen Australia PTY Ltd, Biogen Austria GmbH, Biogen B.V., Biogen Belgium N.V./S.A., Biogen Biotechnology (Shanghai) Co. Ltd, Biogen Brasil Produtos Farmaceuticos LTDA, Biogen Canada Inc., Biogen Chesapeake LLC, Biogen Chile Spa, Biogen Digital Health Inc., Biogen Estonia OU, Biogen Finland OY, Biogen Foundation Inc., Biogen France S.A.S., Biogen GmbH, Biogen Holding I LLC, Biogen Holding II LLC, Biogen Hong Kong Limited, Biogen Hungary KFT, Biogen Idec (Ireland) Ltd., Biogen Idec Biotech India Pvt. Ltd., Biogen Idec Limited, Biogen Idec Research Ltd., Biogen Idec Uruguay SA, Biogen International GmbH, Biogen International Holding Limited, Biogen International Neuroscience GmbH, Biogen Italia S.R.L., Biogen Japan Ltd., Biogen Korea LLC, Biogen Latvia SIA, Biogen Lithuania UAB, Biogen Luxembourg Holding S.a.r.l., Biogen MA Inc., Biogen Management Services GmbH, Biogen Manufacturing Holding LLC, Biogen Mexico S. DE R.L. DE C.V., Biogen NZ Biopharma Ltd., Biogen Netherlands B.V., Biogen New Ventures Inc., Biogen Norway AS, Biogen Pharma d.o.o., Biogen Pharma farmacevtska in biotehnoloska druzba d.o.o., Biogen Poland Sp. z.o.o., Biogen Portugal Sociedade Farmaceutica Unipessoal Lda., Biogen Realty Corporation, Biogen Realty Limited Partnership, Biogen SRO Inc., Biogen Slovakia s.r.o., Biogen Spain S.L., Biogen Sweden AB, Biogen Swiss Investments GmbH, Biogen Swiss Manufacturing GmbH, Biogen Switzerland AG, Biogen Switzerland Holdings GmbH, Biogen Taiwan Limited, Biogen Therapeutics Inc., Biogen Turkey Ilac Ticaret Limited Sirketi, Biogen U.S. Corporation, Biogen U.S. Limited Partnership, Biogen U.S. Pacific LLC, Biogen U.S. West Corporation, Conforma Therapeutics, Conforma Therapeutics Corporation, Convergence Pharmaceuticals, Convergence Pharmaceuticals Holdings Ltd., Convergence Pharmaceuticals Limited, Eidetica Biopharma GmbH, Fumapharm, IDEC Pharmaceuticals Corporation, NightstaRx Limited, Nightstar Europa Limited, Nightstar Inc., Nightstar Therapeutics Limited, Nightstar Therapeutics plc, Old Convergence Pharmaceuticals Limited, Panima Pharmaceuticals AG, Silver Acquisition Co. Ltd., Stromedix Inc., Stromedix Inc., Syntonix Pharmaceuticals Inc., TYSABRI, and Tungsten Bidco Limited.
Read More
How can I contact Biogen?: Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is www.biogen.com. The biotechnology company can be reached via phone at (617) 679-2000, via email at ir@biogen.com, or via fax at 617-679-2617.

This page (NASDAQ:BIIB) was last updated on 9/23/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial